Palbociclib CAS 571190-30-2 Purity >99.5% (HPLC) API Factory

Chemical Name: Palbociclib  CAS: 571190-30-2 Purity: >99.5% (HPLC)  Appearance: White or Off-White Powder  API In the Treatment of Breast Cancer High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Palbociclib Related Intermediates: Palbociclib CAS 571190-30-2 5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5 5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7 tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4
Item Specifications
Appearance White or Off-White Powder
1H NMR Spectrum Consistent With Structure
HPLC Consistent With Structure
Related Substances
Individual Impurity <0.50%
Total Impurities <1.00%
Loss on Drying <0.50%
Residue on Ignition <0.10%
Heavy Metals <10ppm
Purity / Analysis Method >99.5% (HPLC)
Test Standard Enterprise Standard
Usage API, In the Treatment of Breast Cancer

Description:

Specifications:

Package & Storage:

Chemical Name Palbociclib
Synonyms PD-0332991; Otava-Bb 1115529; Ibrance
CAS Number 571190-30-2
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C24H29N7O2
Molecular Weight 447.54
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Palbociclib (CAS: 571190-30-2) is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. Palbociclib is the first representative of the new drug class of cyclin-dependent kinase inhibitors. This effect limits cell proliferation (cell growth and division). It is used as an antineoplastic agent in advanced or metastatic breast cancer.  

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours